Skip to main content

Table 3 Factors associated with the occurrence of neurological severe adverse effects following ivermectin treatment in DRC between 2003 and 2017 – univariate analysis

From: Analysis of severe adverse effects following community-based ivermectin treatment in the Democratic Republic of Congo

Parameter category % NSAE Crude OR (95%-CI) P-value
Sex
 Male 509 (76.0) 3.9 (2.9–5.4) < 0.001
 Female 122 (44.4) 1  
Age (years)
  ≤ 18 14 (22.2) 1  
 19–35 301 (74.7) 10,3 (5.5–19.5) < 0.001
  ≥ 36 316 (65.9) 6.8 (3.6–12.7) < 0.001
Alcohol consumption 24 h before ivermectin treatment
 Yes 181 (87.9) 4.6 (2.9–7.6) < 0.001
 No 450 (60.9) 1  
Hemp consumption 24 h before ivermectin treatment
 Yes 89 (80.9) 2.3 (1.4–3.9) < 0.001
 No 542 (64.9) 1  
Associated diseases
 Loiasis    
 Yes 590 (68.8) 2.5 (1.6–3.9) < 0.001
 No 41 (46.6) 1  
Uncomplicated malaria
 Yes 610 (66.7) 1  
 No 21 (70.0) 1.2 (0.5–2.6) 0.703
Diabetes
 Yes 12 (100.0) NA  
 No 619 (66.4)   
  1. NSAE = neurological severe adverse effects, OR = odds ratio, CI = confidence interval